• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025

    3/23/25 4:00:00 PM ET
    $UBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UBX alert in real time by email

    SOUTH SAN FRANCISCO, Calif., March 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host a virtual investor event on Monday, March 24, 2025, at 8:00 AM ET. To register, click here.

    The event will feature prominent ophthalmology key opinion leader (KOL) Robert Bhisitkul, MD, PhD from the UCSF School of Medicine, who will join company management to review 24- and 36-week results from the Phase 2b ASPIRE study evaluating the safety and efficacy of UBX1325 in patients with DME. UBX1325 is a potent BCL-xL inhibitor that acts via a senolytic mechanism of action, with the potential to improve long-term visual outcomes.

    A live question and answer session will follow the formal presentations.

    About UBX1325

    UBX1325 is an investigational compound being studied in retinal diseases, including DME, and is not approved for any use in any country. UBX1325 is a potent small molecule inhibitor of BCL-xL, a member of the BCL-2 family of apoptosis regulating proteins. UBX1325 is designed to inhibit the function of proteins that senescent cells rely on for survival. The Phase 2 BEHOLD study in patients with DME demonstrated that a single injection of UBX1325 resulted in a statistically significant and clinically meaningful improvement in mean BCVA through 48 weeks compared to sham treatment. In preclinical studies, UNITY has demonstrated that targeting BCL-xL with UBX1325 preferentially eliminated senescent cells from diseased tissue while sparing cells in healthy tissue. UNITY's goal with UBX1325 is to transformationally improve real-world outcomes for patients with retinal disease.

    About UNITY

    UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on X and LinkedIn. 

    Media Contact

    Inizio Evoke Comms

    Katherine Smith

    [email protected]

    Investor Contact

    LifeSci Advisors, LLC

    Joyce Allaire

    [email protected]



    Primary Logo

    Get the next $UBX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UBX

    DatePrice TargetRatingAnalyst
    5/27/2025$2.00Buy → Neutral
    H.C. Wainwright
    5/16/2025$6.00 → $1.00Outperform → Neutral
    Mizuho
    8/22/2024$8.00Buy
    Rodman & Renshaw
    11/16/2023$2.00 → $4.00Neutral → Outperform
    Wedbush
    1/4/2022$4.00Neutral → Buy
    Roth Capital
    1/4/2022Neutral → Buy
    ROTH Capital
    11/10/2021$5.00 → $7.00Neutral → Buy
    Mizuho
    6/28/2021Sell → Buy
    Citigroup
    More analyst ratings